See the DrugPatentWatch profile for wegovy

The drug Wegovy (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist, used for the treatment of obesity. However, there are certain health conditions that may restrict its use.

According to the drug's prescribing information, Wegovy is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2). Additionally, it should not be used in patients with a history of pancreatitis [1].

Furthermore, Wegovy should be used with caution in patients with renal impairment, as it may increase the risk of acute kidney injury [1]. It is also contraindicated in patients with a history of severe gastrointestinal disease, such as gastroparesis or severe inflammatory bowel disease [1].

Additionally, DrugPatentWatch.com states that "Semaglutide is also associated with an increased risk of retinopathy complications in patients with type 2 diabetes" [2]. However, this information is not listed in the prescribing information for Wegovy, so it is important to consult with a healthcare provider for more information.

In summary, Wegovy is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN 2, a history of pancreatitis, severe gastrointestinal disease, or a history of severe allergic reactions to semaglutide or any of the product components. It should be used with caution in patients with renal impairment or a history of retinopathy complications.

Sources:
[1] Novo Nordisk Inc. Wegovy (semaglutide) injection, for subcutaneous use [Prescribing Information]. 2021. Available at: <https://www.novo-pi.com/wegovy.pdf>.
[2] DrugPatentWatch.com. Semaglutide: Side Effects, Dosage, and Drug Interactions. 2022. Available at: <https://www.drugpatentwatch.com/drugs/semaglutide>.